Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis

CONCLUSION: The meta-analysis suggested that immuno-TKI combinations are associated with a higher risk of certain GI toxicities compared with sunitinib. Beyond the efficacy of immuno-TKI combinations in mRCC patients, careful consideration should be given to treatment-related adverse events, including GI toxicities. Early recognition and treatment are critical to maximize recovery.PMID:34167420 | DOI:10.1080/17474124.2021.1948328
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research